A Phase 1B/2 Study to Evaluate the Safety and Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose Ara-C, or Decitibine in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Description: 

To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of PF-04449913 in combination with low dose ARA-C, decitabine (Arm B) or cytarabine/daunorubicin (Arm C) when administered to adults with previously untreated AML or high-risk MDS.

Study Number: 

PH 213212

Phase: 
I
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01546038

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.